| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5567817 | PF PRISM CV | Triazole antifungal agents |
May, 2016
(7 years ago) | |
| US6632803 | PF PRISM CV | Pharmaceutical formulations containing voriconazole |
Jun, 2018
(5 years ago) | |
Vfend is owned by Pf Prism Cv.
Vfend contains Voriconazole.
Vfend has a total of 2 drug patents out of which 2 drug patents have expired.
Expired drug patents of Vfend are:
- US5567817
- US6632803
Vfend was authorised for market use on 24 May, 2002.
Vfend is available in tablet;oral, injectable;intravenous, for suspension;oral dosage forms.
Vfend can be used as treatment of fungal infections.
The generics of Vfend are possible to be released after 29 January, 2022.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Jan 29, 2022 |
Drugs and Companies using VORICONAZOLE ingredient
Market Authorisation Date: 24 May, 2002
Treatment: Treatment of fungal infections
Dosage: TABLET;ORAL; INJECTABLE;INTRAVENOUS; FOR SUSPENSION;ORAL
How can I launch a generic of VFEND before it's drug patent expiration?
More Information on Dosage
VFEND family patents
